Newsletters
- All
- AMR Action Fund
- Can you help?
- CARB-X
- CDC
- FDA
- Government Action
- Jobs
- Meetings
- PK & PK-PD
- Push/Pull
- R&D Insight
- RFPs
- Something Different
- Summaries
- Wellcome Trust
- WHO
- Wonkish
- All
- AMR Action Fund
- Can you help?
- CARB-X
- CDC
- FDA
- Government Action
- Jobs
- Meetings
- PK & PK-PD
- Push/Pull
- R&D Insight
- RFPs
- Something Different
- Summaries
- Wellcome Trust
- WHO
- Wonkish
#AMRSOS: Imipenem-relebactam withdrawn from the US market
Dear All: Oh, no! Hot on the heels of the excellent talk at GAMRIC by Karen Bush in which the ...
Read More >
Global Review of Pull Incentives / PASTEUR Sign-On Letter
Dear All: We need to make Pull incentives work! On this theme, our first topic for today is an opportunity ...
Read More >
CARB-X: 2nd 2026 application call; 5x impact of CARB-X funding!
Dear All: CARB-X have just announced their 2nd 2026 call for applications. There are 4 thematic areas for your proposals: ...
Read More >
#AMRSOS! The (human) cost of AMR: Data from 19 countries in Asia
Dear All: Significantly strengthening our database documenting the human cost of AMR, we now have an impressive survey of mortality ...
Read More >
Milken webinar: Innovative financing models for antimicrobials
Note: I’ve been away on holiday (see the newsletter’s postscript) and so there are multiple new items in both the ...
Read More >
AWaRe antibiotic usage – Is 70% Access a good target?
Dear All: An important and instructive analysis of optimal global antibiotic usage targets has just been published in Lancet Public ...
Read More >
WHO: Virtual discussion on challenges of evidence generation
Dear All: WHO have announced a very interesting 2-h virtual dialogue on optimal evidence generation across the antibiotic R&D lifecycle! ...
Read More >
FDA guidance on Substantial Effectiveness; EMA concept paper on Evaluation of Antifungal Agents): Comments sought!
Dear All: Both FDA and EMA have very recently released important documents for comment. See below the links and commentary ...
Read More >
WHO Webinars: Pediatric antibiotic R&D and Bacteriophage Community of Practice
Dear All: Two important webinars have just been announced! 22 July (virtual, 2-3.30p CET): The WHO AMR Department and the ...
Read More >
CDC: Funding opportunities (1 each) in US, Africa, and Asia
Dear All: CDC have recently posted this eclectic mixture of funding opportunities that circle the globe! Funding opportunity: CDC-RFA-CK-26-0107 Title: ...
Read More >
PACCARB returns! 16 June 2026 virtual meeting
Dear All: Without much fanfare, we have an announcement that PACCARB (the US Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria) ...
Read More >
EUR 20m funding for next-gen diagnostics for LRTIs (Novo Nordisk Foundation)
Dear All: I have just learned of a recently opened grant program from NNF (Novo Nordisk Foundation) that seeks to ...
Read More >
Economic modeling of the value of rapid diagnostics
Dear All (and again with thanks to Arjun Srinivasan for co-authoring this pair of newsletters): In parallel with the newsletter ...
Read More >
Limits on measuring the impact of rapid antimicrobial susceptibility testing (AST)
Dear All (and with thanks to Arjun Srinivasan for co-authoring this wonkish newsletter — prepare yourself! Know also that we’ve ...
Read More >
BARDA seeks info on Phase 2+ antifungals for Candida and Aspergillus
Dear All: As discussed in prior newsletters, BARDA is constantly working to ensure it has adequate medical countermeasures (MCMs) for ...
Read More >
CARB-X seeks two Assistant Directors of External Affairs
Dear All: Starting to get caught up after some time on vacation! For today, we have announcement by CARB-X of ...
Read More >
DTR Gram-negative infections: Are new antibiotics making a difference?
Dear All (and with thanks to Aaron Dane for co-authoring this newsletter AND inhale, exhale … this is going to be ...
Read More >
AMR Science-Policy Symposia (ESCMID 2026): Smart policies for lean times
Dear All: ESCMID Global once again held an afternoon of sessions focused on the intersection of AMR-related science and policy. ...
Read More >
Wellcome Leap: $50m for gut-sparing approaches to antibiotic delivery
Dear All: I’ve just learned of a funding call from Wellcome Leap entitled “Focused antibiotics.” The thesis of the call ...
Read More >
Anti-Gram-negative beta-lactams in jeopardy: The rise of PBP3 mutations
Dear All (and with thanks to Robert Bonomo and Patricia Bradford for guiding me on this newsletter; anything that’s correct ...
Read More >